O-97 Patterns of chemotherapy (CT) for non-small cell lung cancer (NSCLC) patients (pts): an analysis of regional cancer registry data in Rotterdam (the Netherlands)

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S31-S32
Author(s):  
Jan P. van Meerbeeck ◽  
Claudia J.C. Meurs ◽  
Ronald Damhuis
Keyword(s):  
Lung Cancer ◽  
The Netherlands ◽  
Small Cell Lung Cancer ◽  
Cancer Registry ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Registry Data ◽  
Small Cell Lung ◽  
Cancer Registry Data ◽  
Nsclc Patients

scholarly journals Trends in Small-Cell Lung Cancer Survival in 1993–2006 Based on Population-Based Cancer Registry Data in Japan

2019 ◽  
Vol 29 (9) ◽  
pp. 347-353 ◽  
Author(s):  
Isao Oze ◽  
Hidemi Ito ◽  
Yoshikazu Nishino ◽  
Masakazu Hattori ◽  
Tomio Nakayama ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Registry ◽  
Cell Lung Cancer ◽  
Cancer Survival ◽  
Population Based ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Registry Data ◽  
Lung Cancer Survival

P1523TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER IN DIALYSIS PATIENTS; FINDINGS FROM OSAKA CANCER REGISTRY DATA

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
NANAMI KIDA ◽  
Yoshiharu Tsubakihara ◽  
Toshitaka Morishima ◽  
Ryo Sato ◽  
Isao Miyashiro
Keyword(s):  
Lung Cancer ◽  
Survival Rate ◽  
Small Cell Lung Cancer ◽  
Cancer Registry ◽  
Advanced Nsclc ◽  
Small Cell ◽  
Dialysis Patients ◽  
Small Cell Lung ◽  
Cancer Registry Data ◽  
Nsclc Patients

Abstract Background and Aims Recent advances in dialysis technic for end-stage renal disease have resulted in a longer survival. Consequently, they have an increased risk of suffering from various neoplastic diseases. The survival outcome and treatment rate in non-small cell lung cancer(NSCLC) patients on dialysis has not been well evaluated. In patients with unresectable stage disease, chemotherapy may best be started soon after the diagnosis of unresectable NSCLC has been made. The aim of this study was to investigate the practice pattern and survival rate in advanced NSCLC patients on dialysis. Method This retrospective study used population-based cancer registry data from Osaka Prefecture, Japan and administrative claims data produced under the Diagnosis Procedure Combination reimbursement system. We performed record linkage between these datasets to obtain patient-level information on dialysis, cancer diagnoses, treatment, and vital statuses. Patients who were diagnosed with advanced NSCLC between 2010 and 2015 and were at the age of 80 years or younger. We calculated the performance proportions of chemotherapy (including molecular-targeted drugs) in dialysis patients and non-dialysis chemotherapy. In addition, we computed one-year survival rate of patients in dialysis patients who underwent chemotherapy and who did not undergo. Results We identified 42 dialysis patients with a median age of 71 years and 18,425 non-dialysis patients with a median age of 70 years who were diagnosed with advanced NSCLC. Dialysis patients (n=11, 26.2 %) were less likely to receive chemotherapy when compared with non-dialysis patients (n=12247, 66.3%). Among dialysis patients, there was no significant difference in 1-year survival rate between the receipt (40.0%) and the non-receipt (29.6%) of chemotherapy (Log-rank test, p=0.41). Conclusion Dialysis patients might receive suboptimal treatment for advanced NSCLC. Further studies are needed to assess whether chemotherapy improves survival outcomes in dialysis patients with advanced NSCLC.

scholarly journals Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3828
Author(s):  
Anello Marcello Poma ◽  
Rossella Bruno ◽  
Iacopo Pietrini ◽  
Greta Alì ◽  
Giulia Pasquini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Cell ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Durable Response ◽  
Nsclc Patients

Pembrolizumab has been approved as first-line treatment for advanced Non-small cell lung cancer (NSCLC) patients with tumors expressing PD-L1 and in the absence of other targetable alterations. However, not all patients that meet these criteria have a durable benefit. In this monocentric study, we aimed at refining the selection of patients based on the expression of immune genes. Forty-six consecutive advanced NSCLC patients treated with pembrolizumab in first-line setting were enrolled. The expression levels of 770 genes involved in the regulation of the immune system was analysed by the nanoString system. PD-L1 expression was evaluated by immunohistochemistry. Patients with durable clinical benefit had a greater infiltration of cytotoxic cells, exhausted CD8, B-cells, CD45, T-cells, CD8 T-cells and NK cells. Immune cell scores such as CD8 T-cell and NK cell were good predictors of durable response with an AUC of 0.82. Among the immune cell markers, XCL1/2 showed the better performance in predicting durable benefit to pembrolizumab, with an AUC of 0.85. Additionally, CD8A, CD8B and EOMES showed a high specificity (>0.86) in identifying patients with a good response to treatment. In the same series, PD-L1 expression levels had an AUC of 0.61. The characterization of tumor microenvironment, even with the use of single markers, can improve patients’ selection for pembrolizumab treatment.

Sign in / Sign up

Export Citation Format

Share Document